Program Information
A Feasibility Study of Independent Dose Verification for Vero4DRT
M Yamashita1,3*, R Takahashi2 , M Kokubo1,3 , K Takayama3,1 , H Tanabe3 , M Sueoka3 , M Ishii1 , N Okuuchi3 , Y Iwamoto1 , H Tachibana4 , (1) Kobe City Medical Center General Hospital, Kobe, Hyogo, (2) Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto, Tokyo, (3) Institute of Biomedical Research and Innovation, Kobe, Hyogo, (4) National Cancer Center, Kashiwa, Chiba
Presentations
SU-F-T-268 (Sunday, July 31, 2016) 3:00 PM - 6:00 PM Room: Exhibit Hall
Purpose: Vero4DRT (Mitsubishi Heavy Industries Ltd.) has been released for a few years. The treatment planning system (TPS) of Vero4DRT is dedicated, so the measurement is the only method of dose verification. There have been no reports of independent dose verification using Clarkson-based algorithm for Vero4DRT. An independent dose verification software program of the general-purpose linac using a modified Clarkson-based algorithm was modified for Vero4DRT. In this study, we evaluated the accuracy of independent dose verification program and the feasibility of the secondary check for Vero4DRT.
Methods: iPlan (Brainlab AG) was used as the TPS. PencilBeam Convolution was used for dose calculation algorithm of IMRT and X-ray Voxel Monte Carlo was used for the others. Simple MU Analysis (SMU, Triangle Products, Japan) was used as the independent dose verification software program in which CT-based dose calculation was performed using a modified Clarkson-based algorithm. In this study, 120 patients’ treatment plans were collected in our institute. The treatments were performed using the conventional irradiation for lung and prostate, SBRT for lung and Step and shoot IMRT for prostate. Comparison in dose between the TPS and the SMU was done and confidence limits (CLs, Mean ± 2SD %) were compared to those from the general-purpose linac.
Results: As the results of the CLs, the conventional irradiation (lung, prostate), SBRT (lung) and IMRT (prostate) show 2.2 ± 3.5% (CL of the general-purpose linac: 2.4 ± 5.3%), 1.1 ± 1.7% (-0.3 ± 2.0%), 4.8 ± 3.7% (5.4 ± 5.3%) and -0.5 ± 2.5% (-0.1 ± 3.6%), respectively. The CLs for Vero4DRT show similar results to that for the general-purpose linac.
Conclusion: The independent dose verification for the new linac is clinically available as a secondary check and we performed the check with the similar tolerance level of the general-purpose linac.
Funding Support, Disclosures, and Conflict of Interest: This research is partially supported by Japan Agency for Medical Research and Development (AMED)
Contact Email: